Form 8-K · Current Report · Filed 2025-05-07
Revolution Medicines Announces Q1 2025 Financial Results and Corporate Updates
Revolution Medicines, Inc. reported its financial results for the quarter ended March 31, 2025, showing a net loss of $213.4 million, compared to a net loss of $116.0 million for the same period in 2024. The company discussed strong execution of its Phase 3 trials for daraxonrasib, with new clinical data supporting development strategies for RAS mutant NSCLC. Additionally, Anthony Mancini joined as the new chief global commercialization officer. The company's cash position was $2.1 billion as of March 31, 2025.
- Filer
- Revolution Medicines Inc. RVMD · NASDAQ
- Filed
- Accession
- 0000950170-25-065618
- CIK
- 0001628171
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$37.44
Next session
+11.9%
Since filing
+400.9%
Latest close
$187.53
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVMD reporting the same item, with the next session's move:
Exhibits (1)
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Never miss another RVMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.